It's all good news at Protherics.

Liarspoker, what happened at 10.00 was a load of buying coming in for a stock which had retraced too much :o))

This was what the FT said - even the minimum target of 90p will reward buyers at the current price:

"FT Comment

*This is a transformational deal for Protherics and gives it a cash cushion to advance the rest of its pipeline. It is not yet known how the AstraZeneca payments will be recognised by Protherics. The company is still forecast to make pre-tax losses of between £4.5m and £6m in the year to March. Furthermore, valuing drugs portfolios is always difficult. But the group should also benefit from the wholly-owned Voraxaze, which combats the toxicity of cancer drugs, and is due to hit the market in 2006. Analysts have share price targets from 90p to 150p, which suggest there is more upside to come."